The influence of temperature treatment before cryopreservation on the viability and potency of cryopreserved and thawed CD34 + and CD45 + cord blood cells

Schwandt, Svenja; Liedtke, Stefanie; Kögler, Gesine

doi:10.1016/j.jcyt.2017.05.005

Cited by 7 publications

(3 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study by Guttridge et al [61] found that pre-cryopreservation storage time significantly affected the viability of CD34+ cells from UCB after cryopreservation, suggesting that extended pre-cryopreservation should be avoided. This finding is consistent with results of another study by Schwandt et al [62], which showed that the highest viability for cord blood cells was obtained when cells were cryopreserved directly after collection. The temperature at which cells are stored before freezing may also affect the cryopreservation outcome.…”

Section: Additional Considerationssupporting

confidence: 93%

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Hornberger

McKenna

et al. 2019

Transfus Med Hemother

View full text Add to dashboard Cite

Hematopoietic stem cell (HSC) therapy is widely used to treat a growing number of hematological and non-hematological diseases. Cryopreservation of HSCs allows for cells to be transported from the site of processing to the site of clinical use, creates a larger window of time in which cells can be administered to patients, and allows sufficient time for quality control and regulatory testing. Currently, HSCs and other cell therapies conform to the same cryopreservation techniques as cells used for research purposes: cells are cryopreserved in dimethyl sulfoxide (DMSO) at a slow cooling rate. As a result, HSC therapy can result in numerous adverse symptoms in patients due to the infusion of DMSO. Efforts are being made to improve the cryopreservation of HSCs for clinical use. This review discusses advances in the cryopreservation of HSCs from 2007 to the present. The preclinical development of new cryoprotectants and new technology to eliminate cryoprotectants after thawing are discussed in detail. Additional cryopreservation considerations are included, such as cooling rate, storage temperature, and cell concentration. Preclinical cell assessment and quality control are discussed, as well as clinical studies from the past decade that focus on new cryopreservation protocols to improve patient outcomes.

show abstract

Section: Additional Considerationssupporting

confidence: 93%

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Hornberger

McKenna

et al. 2019

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…[108] Schwandt et al conducted another study and found that the storage temperature of the cells before cryopreservation also affects the result of cryopreservation, which was evaluated in the case of cryopreservation promptly following collection, showing the highest viability. [109] Fry et al showed the hematopoietic stem cells were held at 4-8 °C in order to avoid considerable loss of cell potency due to room temperature storage and delayed cryopreservation, and to ensure greater post-thaw power of hematopoietic progenitor cell grafts. [110,111]…”

Section: Prefreezing Storagementioning

confidence: 99%

Cryopreservation: A Comprehensive Overview, Challenges, and Future Perspectives

et al. 2023

View full text Add to dashboard Cite

Cryopreservation is the most prevalent method of long‐term cell preservation. Effective cell cryopreservation depends on freezing, adequate storage, and correct thawing techniques. Recent advances in cryopreservation techniques minimize the cellular damage which occurs while processing samples. This article focuses on the fundamentals of cryopreservation techniques and how they can be implemented in a variety of clinical settings. The article presents a brief description of each of the standard cryopreservation procedures, such as slow freezing and vitrification. Alongside that, the membrane permeating and nonpermeating cryoprotectants are briefly discussed, along with current advancements in the field of cryopreservation and variables influencing the cryopreservation process. The diminution of cryoinjury incurred by the cell via the resuscitation process will also be highlighted. In the end application of cryopreservation techniques in many fields, with a special emphasis on stem cell preservation techniques and current advancements presented. Furthermore, the challenges while implementing cryopreservation and the futuristic scope of the fields are illustrated herein. The content of this review sheds light on various ways to enhance the output of the cell preservation process and minimize cryoinjury while improving cell revival.

show abstract

“…In our study, there is clear evidence that the cellular population has become skewed post thaw. As granulocytes are particularly sensitive to loss of viability [28] the differences in fresh and frozen cell proportions can, at least in part, be explained by loss of CD3 negative cells. However, this does not account for differences in the Treg/CD3+ cell ratios.…”

Section: Plos Onementioning

confidence: 99%

Enumerating regulatory T cells in cryopreserved umbilical cord blood samples using FOXP3 methylation specific quantitative PCR

et al. 2020

View full text Add to dashboard Cite

Background Allogeneic haematopoietic cell transplantation (HCT) is a curative therapy for severe haematological disorders. However, it carries significant risk of morbidity and mortality. To improve patient outcomes, better graft selection strategies are needed, incorporating HLA matching with clinically important graft characteristics. Studies have shown that the cellular content of HCT grafts, specifically higher ratios of T regulatory (Tregs)/T cells, are important factors influencing outcomes when using adult peripheral blood mobilised grafts. So far, no equivalent study exists in umbilical cord blood (CB) transplantation due to the limitations of cryopreserved CB samples. Study design and methods To establish the most robust and efficient way to measure the Treg content of previously cryopreserved CB units, we compared the enumeration of Treg and CD3+ cells using flow cytometry and an epigenetic, DNA-based methodology. The two methods were assessed for their agreement, consistency and susceptibility to error when enumerating Treg and CD3+ cell numbers in both fresh and cryopreserved CB samples. Results Epigenetic enumeration gave consistent and comparable results in both fresh and frozen CB samples. By contrast, assessment of Tregs and CD3+ cells by flow cytometry was only possible in fresh samples due to significant cell death following cryopreservation and thawing. Conclusion Epigenetic assessment offers significant advantages over flow cytometry for analysing cryopreserved CB; similar cell numbers were observed both in fresh and frozen samples. Furthermore, multiple epigenetic assessments can be performed from DNA extracted from small cryopreserved CB segments; often the only CB sample available for clinical studies.

show abstract

The influence of temperature treatment before cryopreservation on the viability and potency of cryopreserved and thawed CD34 + and CD45 + cord blood cells

Cited by 7 publications

References 60 publications

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Cryopreservation: A Comprehensive Overview, Challenges, and Future Perspectives

Enumerating regulatory T cells in cryopreserved umbilical cord blood samples using FOXP3 methylation specific quantitative PCR

Contact Info

Product

Resources

About